Aegerion raises revenue forecast; shares jump 26 percent

[riky]

Aegerion raises revenue forecast; shares jump 26 percent

(Reuters) - Aegerion Pharmaceuticals Inc raised its full-year revenue forecast following strong sales growth for its cholesterol-lowering drug Juxtapid in the second quarter, sending its shares up as much as 26 percent. The number of patients receiving the therapy rose 185 percent in the quarter from the first quarter, while new patients waiting to receive the drug more than doubled. Juxtapid was approved in December as an alternative treatment for patients who have a genetic predisposition to high cholesterol. The company launched the drug in late-January. ...

Source: You are not allowed to view links. Register or Login